GOSS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Gossamer Bio is not a good buy right now for a beginner with a long-term horizon and $50,000-$100,000 to deploy. The stock is trading after a major clinical disappointment, analyst downgrades are piling up, hedge funds are selling, and the regulatory path remains unclear. Despite a small pre-market uptick, the setup is still weak and the current price does not offer a compelling long-term entry. I would not buy this stock now.
GOSS is in a bearish trend. The moving averages are aligned bearishly with SMA_200 > SMA_20 > SMA_5, which confirms downside pressure. RSI_6 at 46.58 is neutral, so there is no oversold rebound signal. MACD histogram is slightly positive at 0.0183 but contracting, suggesting momentum is fading rather than strengthening. Price is below the pivot at 0.391 and near support at 0.337, with resistance at 0.444 and 0.478. The broader pattern data also points to weakness, with an 80% probability estimate for further downside over the next day, week, and month.
["2025/Q4 revenue grew 47.13% YoY to 13.799M", "Gross margin remained at 100%, which is typical for a biotech company with limited revenue base", "Oppenheimer remains positive on seralutinib potential and sees possible re-rating if regulatory discussions improve", "Low put-call ratios indicate some speculative call-side interest"]
["PROSERA Phase 3 missed the primary endpoint, which triggered the major selloff", "Multiple class action lawsuits were filed in late April and early May 2026", "Cantor Fitzgerald downgraded the stock to Neutral and cited unclear regulatory path", "Several other firms sharply cut price targets and ratings", "Hedge funds are selling aggressively, up 535.94% last quarter", "Debt concerns remain elevated relative to cash", "No recent congress trading data is available", "No AI Stock Picker or SwingMax signal today", "Price trend expectations point to further downside"]
In 2025/Q4, Gossamer Bio reported revenue of 13.799M, up 47.13% year over year, which shows strong top-line growth. However, net income was still deeply negative at -47.238M, and EPS was -0.20, even though both losses improved versus last year. This means the latest quarter showed better operating progress, but the company is still unprofitable and the business remains highly dependent on clinical/regulatory outcomes. Latest quarter season: 2025/Q4.
Analyst sentiment has turned sharply negative. Since late February and March 2026, multiple firms downgraded the stock or cut targets aggressively: Wedbush, Goldman Sachs, Leerink, Barclays, and Cantor all turned more cautious, while H.C. Wainwright and Oppenheimer kept bullish ratings but still reduced targets materially. The overall Wall Street view is now more bearish than bullish: the cons are the failed Phase 3 readout, uncertain FDA path, debt overhang, and financing risk. The main pro side is that some analysts still believe seralutinib could have a narrow approval path and eventual re-rating if future regulatory discussions or additional data improve the story.
